Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C

被引:42
作者
Wu, J
Chen, S [1 ]
Gui-Qiang, W
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Infect Dis, Harbin 150086, Peoples R China
[2] PeiKing Univ, Hosp 1, Dept Infect Dis, PeiKing, Peoples R China
关键词
fatty liver; genotype; hepatitis C; insulin; sustained virologic response;
D O I
10.1111/j.1478-3231.2006.01219.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: Hepatic steatosis is a histological feature in patients with chronic hepatitis C (CHC) and adversely affects the virologic response rates to anti-hepatitis C virus (HCV) therapy. The aim of this study is to investigate whether the fatty liver and related factors have impact on the efficacy in CHC treated with peginterferon and ribavirin, and the associations between HCV genotyping and fatty liver. Methods: Ninety-eight patients received subcutaneously 180 mu g peginterferon alpha-2a once a week plus ribavirin. HCV genotypes and the levels of plasma insulin of patients were measured. Fatty liver was detected by B ultrasound. The body mass index (BMI), waist-to-hip ratio (WHR) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated. Results: Among 98 CHC patients, 38 (38.8%) were infected with genotype 1; 44 (44.9%) with genotype 2; 13 (13.3%) with genotype 3; 3 (3.0%) with indeterminate genotype. The prevalence of fatty liver was 10.5%, 11.4%, 38.5% in patients infected with HCV genotype 1, 2, 3, respectively, which suggested that the distribution of fatty liver in different HCV genotypes was imbalanced (chi(2)=6.758, P=0.034). In univariate analysis, the efficacy of combination therapy was significantly associated with BMI (P=0.011), WHR (P=0.024), the levels of plasma insulin (P=0.001), genotype (P=0.036), presence of fatty liver (P=0.028), treatment dosage and duration (P=0.012) and HOMA-IR (P=0.002). With binary logistic regression analysis, the plasma insulin levels and HOMA-IR showed independent predictors to the efficacy of antiviral therapy. Conclusion: The prevalence of fatty liver in HCV genotype 3 was markedly higher than that of other genotypes. The BMI, WHR, the levels of plasma insulin, genotype, presence of fatty liver, treatment dosage and duration and HOMA-IR were associated with the sustained virologic response. The level of plasma insulin and HOMA-IR were independent factors for predicting effect of antiviral therapy.
引用
收藏
页码:166 / 172
页数:7
相关论文
共 50 条
  • [41] Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (Interferon-ribavirin therapy)
    Bahra, Marcus
    Neumann, Ulf P.
    Jacob, Dietmar
    Langrehr, Jan M.
    Berg, Thomas
    Neuhaus, Ruth
    Neuhaus, Peter
    TRANSPLANTATION, 2007, 83 (03) : 351 - 353
  • [42] Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists
    Hofmann, WP
    Bock, H
    Weber, C
    Tacke, W
    Pfaff, R
    Kihn, R
    Moog, G
    Kellner, HU
    Schöfer, M
    Frick, B
    Berg, P
    Rambow, A
    Friedrich-Rust, M
    Hermann, E
    Sarrazin, C
    Zeuzem, S
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2006, 44 (01): : 25 - 31
  • [43] Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
    Foster, Graham R.
    Irving, William L.
    Cheung, Michelle C. M.
    Walker, Alex J.
    Hudson, Benjamin E.
    Verma, Suman
    McLauchlan, John
    Mutimer, David J.
    Brown, Ashley
    Gelson, William T. H.
    MacDonald, Douglas C.
    Agarwal, Kosh
    JOURNAL OF HEPATOLOGY, 2016, 64 (06) : 1224 - 1231
  • [44] Hepatic lipogranulomas in patients with chronic liver disease: Association with hepatitis C and fatty liver disease
    Henry C Bodenheimer
    David J Clain
    Albert D Min
    Neil D Theise
    World Journal of Gastroenterology, 2010, 16 (40) : 5065 - 5069
  • [45] Hepatic lipogranulomas in patients with chronic liver disease: Association with hepatitis C and fatty liver disease
    Zhu, Hongfa
    Bodenheimer, Henry C., Jr.
    Clain, David J.
    Min, Albert D.
    Theise, Neil D.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (40) : 5065 - 5069
  • [46] Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C
    Mulhall, BP
    Younossi, Z
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (01) : S23 - S27
  • [47] Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection
    Sharafi, Heidar
    Nikbin, Mehri
    Alavian, Seyed Hoda
    Behnava, Bita
    Alavian, Seyed Moayed
    HEPATITIS MONTHLY, 2017, 17 (06)
  • [48] Antiviral therapy for chronic hepatitis C: past, present, and future
    Norio Hayashi
    Tetsuo Takehara
    Journal of Gastroenterology, 2006, 41 : 17 - 27
  • [49] Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation
    Nair, Satheesh
    Lipscomb, Jeannie
    Eason, James
    TRANSPLANTATION, 2008, 86 (03) : 418 - 422
  • [50] Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C
    Kumar, Sonal
    Jacobson, Ira M.
    JOURNAL OF HEPATOLOGY, 2014, 61 : S91 - S97